Back to List
Program0 Views

Governance & RACI / Phase-Gate Criteria — GLPI-103

July 12, 2026

📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

🧪
Mock / simulation document

This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.

📄
About this document — a plain-language guide

What it is. The governance model, RACI matrix, and phase-gate criteria.

Why it exists. Clear decision rights prevent drift. This defines who is Responsible/Accountable/Consulted/Informed for key activities and the go/no-go criteria at each development gate.

How it is produced here. It is a program-management document: the planning, budgeting, and governance wrapper around the science — how the whole development program is run as a project.

Format & governing standard.


Governance & RACI / Phase-Gate Criteria — GLPI-103

FieldValue
Document IDPM-005
Version1.0
ConfidentialityConfidential — portfolio use

Change History

VersionDateAuthorSummary
1.02026-06-29Project ManagementInitial governance & RACI

1. Governance Bodies

  • Steering Committee: strategic oversight; Phase-gate Go/No-Go decisions.
  • Core Project Team (CPT): cross-functional execution (Clinical, Biostat, RA, CMC, PV, DM, PM).
  • DSMB (independent): unblinded safety oversight (TMF-DSMB).

2. RACI (key deliverables)

DeliverableClinicalBiostat/DMRegulatoryCMCPVPM
Protocol / SAPA/RRCICC
CSR / TLFsARCICI
CDISC datasets / defineIA/RCI
Module 2/3/5 dossierCCA/RR(M3)CC
RMP / safetyCCCA/RI
Budget / timeline / riskCCCCCA/R

(R = Responsible, A = Accountable, C = Consulted, I = Informed.)

3. Phase-Gate Decision Criteria

GateTriggerGo criteria
Gate 1After FIH SAD (101)Acceptable safety/PK
Gate 2After MAD (102)Early efficacy/biomarker signal
Gate 3After Phase 2 PoC (201)Dose–response established → commit Phase 3
Gate 4After Phase 3 (301)Positive benefit–risk → submit

Decisions and rationale are recorded in the Decision Log (PM-DECISION). Cost context per PM-003; risks per PM-004.

Comments (0)

No comments yet. Be the first to say something!